Uptake Patterns of [18F]Fluoroestradiol PET/MRI in Benign Breast Lesions and Molecular Breast Cancer Subtypes
Cancers · 20.02.2026 · 18 (4) · 696
DOI: 10.3390/cancers18040696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 20.02.2026. Verfasst von Thomas Spiegel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Image-Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guer…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Vienna Science and Technology Fund (WWTF), Jubiläumsfonds der Österreichischen Nationalbank.
Abstract (Originalsprache)
Background/Objectives: Estrogen receptor (ER) expression is a key biomarker in breast cancer (BC) and guides endocrine therapy selection. Estrogen receptor-targeted imaging with 16ɑ-[18F]-fluoro-17β-estradiol (18F-FES) PET is recommended in several clinical guidelines for noninvasive assessment of ER status. In clinical practice, 18F-FES PET may also identify ER-negative malignancies or benign breast lesions with variable uptake patterns. This study aimed to systematically characterize 18F-FES PET/MRI uptake patterns in benign breast lesions and across breast cancer subtypes defined by receptor status, histology, and molecular phenotype.
Methods
This retrospective single-center study included 41 women with 50 breast lesions who underwent simultaneous 18F-FES PET/MRI prior to any treatment. Histopathology or long-term follow-up served as the standard of reference. Maximum and mean standardized uptake values (SUVmax and SUVmean) were derived using MRI-based lesion delineation.
Results
Both benign and malignant breast lesions measuring < 10 mm demonstrated low 18F-FES uptake (SUVmax < 1.00). 18F-FES uptake among benign breast lesions was variable, with SUVmax ranging from 0.44 to 1.57. In contrast, ER-positive lesions ≥ 10 mm exhibited substantially higher 18F-FES uptake (median SUVmax 2.76; range 1.23–9.74) compared with ER-negative tumors of similar size (SUVmax 0.30–0.94). 18F-FES uptake was consistent across histologic BC subtypes and did not differ significantly among ER-positive molecular subtypes. No significant associations were observed with HER2 status or tumor grade.
Conclusions
Awareness of the heterogeneous 18F-FES uptake patterns in benign breast lesions, as well as the limited sensitivity for detecting ER-positive tumors < 10 mm, is essential for accurate image interpretation. 18F-FES PET/MRI enables reliable assessment of ER expression in BC lesions ≥ 10 mm, with uptake patterns remaining consistent across molecular and histologic subtypes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Imaging and Image-Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Department of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY 10065, USA.
ORCID-Profile: Thomas Spiegel, Sazan Rasul, Panagiotis Kapetas, Ivo Rausch, Pascal A T Baltzer, Marcus Hacker, Thomas H Helbich
Förderung
- NCI NIH HHS
- Vienna Science and Technology Fund (WWTF)
- Jubiläumsfonds der Österreichischen Nationalbank
Zitieren
APA
Spiegel, T., Rasul, S., Pötsch, N., Stiglbauer-Tscholakoff, A., Kapetas, P., Nics, L., Gebhart, P., Rausch, I., Bago-Horvath, Z., Clauser, P., Baltzer, P. A. T., Hacker, M., Helbich, T. H., & Pinker, K. (2026). Uptake Patterns of [18F]Fluoroestradiol PET/MRI in Benign Breast Lesions and Molecular Breast Cancer Subtypes. Cancers, 18(4), 696. https://doi.org/10.3390/cancers18040696
Vancouver
Spiegel T, Rasul S, Pötsch N, Stiglbauer-Tscholakoff A, Kapetas P, Nics L, et al. Uptake Patterns of [18F]Fluoroestradiol PET/MRI in Benign Breast Lesions and Molecular Breast Cancer Subtypes. Cancers. 2026;18(4):696. doi:10.3390/cancers18040696
BibTeX
@article{Spiegel2026,
author = {Spiegel, Thomas and Rasul, Sazan and Pötsch, Nina and Stiglbauer-Tscholakoff, Alexander and Kapetas, Panagiotis and Nics, Lukas and Gebhart, Paulina and Rausch, Ivo and Bago-Horvath, Zsuzsanna and Clauser, Paola and Baltzer, Pascal A T and Hacker, Marcus and Helbich, Thomas H and Pinker, Katja},
title = {Uptake Patterns of [18F]Fluoroestradiol PET/MRI in Benign Breast Lesions and Molecular Breast Cancer Subtypes},
journal = {Cancers},
year = {2026},
volume = {18},
number = {4},
pages = {696},
doi = {10.3390/cancers18040696}
}
EUVIMED